Opinion
The American Journal of Managed CareOpinion

US Spending on High-Revenue Rare Disease Drugs in 2022

Median net sales for the 19 drugs in 2022 were $1.97 billion (range, $988 million-$8.36 billion). The drugs with the highest net sales were lenalidomide (Revlimid; $8.36 billion), ...

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th – NV-387 is Effective Against H3N2

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the “Company”), ...

BioCytics Successfully Completes a Key Regulatory Milestone with Recent FDA INTERACT Meeting

BioCytics is pleased to announce they successfully reached a regulatory milestone for de-risking clinical development plans with a productive FDA INTERACT meeting during which they discussed ...
MPR

FDA Approves Poherdy, the First Interchangeable Biosimilar to Perjeta

Poherdy can be dispensed as a substitute for Perjeta without requiring a prescription change from a health care provider.

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

This NDA submission is an important milestone, and it brings gedatolisib one step closer to becoming available for patients with HR+/HER2- advanced breast cancer,” said Brian Sullivan, CEO and ...
Neurology Advisor

Migraine Treatment Reyvow Discontinued, According to FDA

Eli Lilly has made the decision to discontinue manufacturing its migraine therapy Reyvow (lasmiditan), according to the FDA’s Drug Shortages tracker.

The Great GLP-1 Reset: Trump’s Medicare Deal Could Upend Telehealth’s Most Profitable Subscription

Trump’s GLP-1 price deal slashes costs and expands selective Medicare coverage—threatening telehealth startups and sparking a ...

ORASIS PHARMACEUTICALS EXPANDS ACCESS TO QLOSI™ WITH NEW STARTER PACKS FOR EYE CARE PROFESSIONALS, BOLSTERING COMMERICAL ROLLOUT

Orasis Pharmaceuticals, an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities, has announced the availability of Starter Packs of Qlosi™ (pilocarpine hydrochloride ...
BMJ Global Health

Improving Sierra Leone’s skilled health-worker-to-population ratio: how unsalaried and auxiliary health workers are barriers in its path to universal health coverage

Background Achieving Universal Health Coverage (UHC) is one of Sierra Leone’s main health policy goals. To achieve UHC, a ...
pharmaphorum

The value of unstructured data for drug companies

The success of pharmaceutical companies in developing drugs for treating and curing medical conditions is largely dependent on the quality and completeness of data they gather from clinical trials and ...
EuropaWire

Sandoz Expands US Biosimilar Portfolio with TYRUKO for Relapsing Multiple Sclerosis and Crohn’s Disease

(IN BRIEF) Sandoz has announced the US availability of TYRUKO® (natalizumab-sztn), the first FDA-approved biosimilar to Tysabri® for treating relapsing forms of multiple sclerosis and Crohn’s disease.